parsaclisib

phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor

Also Known As:

(4R)-4-(3-((1S)-1-(4-amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; 2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4R)-; INCB050465

Networked: 23 relevant articles (7 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds

Experts

1.	Li, Jia: 4 articles (04/2024 - 11/2020)
2.	DeMarini, Douglas J: 4 articles (09/2023 - 01/2019)
3.	Rappold, Erica: 3 articles (04/2024 - 05/2022)
4.	Chen, Xuejun: 3 articles (04/2024 - 01/2019)
5.	Smith, Michael: 3 articles (03/2024 - 01/2022)
6.	Mehta, Amitkumar: 3 articles (12/2023 - 01/2021)
7.	Zhao, Wanying: 3 articles (12/2023 - 01/2021)
8.	Zheng, Fred: 3 articles (12/2023 - 08/2023)
9.	Zinzani, Pier Luigi: 3 articles (12/2023 - 08/2023)
10.	Coleman, Morton: 3 articles (12/2023 - 01/2021)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2022 - "We undertook a phase Ib study (CITADEL-111) evaluating safety, pharmacokinetics, and efficacy of parsaclisib in Japanese patients with relapsed or refractory B-cell malignancies. " 04/01/2024 - "Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study." 03/01/2024 - "It is of inter-est with respect to efforts in the synthesis of a candidate anti-cancer drug, parsaclisib." 09/01/2023 - "Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. " 08/01/2023 - "Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. "
2.	B-Cell Lymphoma (Lymphoma, B Cell) 05/01/2022 - "Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study." 02/27/2024 - "Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell lymphomas. " 05/01/2022 - "Parsaclisib, a potent, selective, next-generation PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory B-cell lymphoma. " 04/10/2024 - "Parsaclisib combined with SOC therapies had an expected safety profile and promising efficacy in patients with R/R B-cell lymphomas." 04/10/2024 - "Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. "
3.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/01/2023 - "Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit with monotherapy in a phase 2 study in relapsed or refractory (R/R) follicular lymphoma (FL). " 09/01/2023 - "This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy and safety of parsaclisib monotherapy in patients with R/R follicular lymphoma (FL). " 09/01/2023 - "Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study." 12/01/2023 - "Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study."
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/01/2024 - "The CITADEL-101 study (NCT02018861) assessed safety, tolerability, and preliminary efficacy of parsaclisib in patients with relapsed or refractory non-Hodgkin lymphoma. "
5.	Sialadenitis 09/01/2021 - "Parsaclisib mediated improvement of salivary gland inflammation coincided with reduced B-cell activating cytokine (BAFF) in saliva. " 09/01/2021 - "Oral parsaclisib treatment ameliorated the severity of salivary gland inflammation and reduced circulating levels of autoantibodies. " 09/01/2021 - "Parsaclisib reduced autoreactive B-cells and autoantibody levels, and significantly improved nephritis and salivary gland inflammation. "

Related Drugs and Biologics

1.	itacitinib
2.	Bendamustine Hydrochloride
3.	epacadostat
4.	Rituximab (Mabthera)
5.	ibrutinib
6.	obinutuzumab
7.	Autoantibodies
8.	parsaclisib
9.	ruxolitinib
10.	pembrolizumab

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)